Affimed (AFMD) Reports Q4 Loss of EUR0.60/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Affimed (AFMD) Reports Q4 Loss of EUR0.60/sh

Affimed (AFMD) Reports FY22, Provides Operational Update

March 23, 2023 6:31 AM EDT

Affimed N.V. (Nasdaq: AFMD) today reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.

During 2022, we presented data across our pipeline that show our innate cell engagers can deliver unprecedented efficacy when combined with NK cells, can activate and direct cytotoxic T cells to tumor cells, and deliver meaningful single agent activity with a differentiated safety profile, said Adi Hoess, Chief Executive Officer at Affimed. Supported by a cash runway into 2025, our Company is well positioned to execute on our strategic imperatives, with... More